CEO and CFO Roundtables World of Incentives: Stock Options: Benefit or Burden? | Part One
CEO and CFO Roundtables | World of Incentives
This two-part Executive Series Roundtable will discuss compensation package design issues: industry veterans will share their experience with both equity and non-equity components, they try to answer the single most important question: how do you design an incentive program that helps retain top talent?
Stock Options: Benefit or Burden? | Part One
There is an on-going debate if stock options remain a viable tool to motivate life science company staff and management. With the M&A activity as a primary exit route for most private companies the prospect of cashing company stock is nonexistent. So, how are your stock option programs changing and what should your plan look like? With the financial pressures mounting, how do you balance between the wants of your employees and the needs of your investors?
The questions are different for the public companies: short term vs. long term; what is sustainable? Is the Board Compensation Committee review a new reality?
Partner, Hogan Lovells US LLP
CEO, Adynxx, Inc.
Diana M. Petty, SPHR
VP Human Resources & Administration, Metabolex, Inc.
Senior Vice President and CFO, OncoMed Pharmaceuticals Inc.
National Practice Leader, Compensation, Barney & Barney LLC
|What:||CEO and CFO Roundtables
World of Incentives: Stock Options: Benefit or Burden? | Part One
|When:||September 20, 2011
|Where:||OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
|Attire:||Business attire suggested|
|Attendance:||RSVP by September 16th is required
No on-site registrations accepted
Open to C-Suite Executives of Life Sciences Companies Only.
|Cost:||BayBio Members – FREE
Non-Members – $75.00